| JVMCX | VVONX | JVMCX / VVONX | |
| Total Expense Ratio | 1.85 | 0.74 | 250% |
| Annual Report Gross Expense Ratio | 1.86 | 0.74 | 251% |
| Fund Existence | 15 years | 15 years | - |
| Gain YTD | 10.086 | 21.757 | 46% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 1000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 23.2B | 9.31B | 249% |
| Annual Yield % from dividends | 0.00 | 0.38 | - |
| Returns for 1 year | 6.34 | 29.03 | 22% |
| Returns for 3 years | 15.57 | 84.13 | 19% |
| Returns for 5 years | 4.47 | 67.34 | 7% |
| Returns for 10 years | 52.32 | 190.66 | 27% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FIJYX | 49.34 | 1.26 | +2.62% |
| Fidelity Advisor Biotechnology Z | |||
| PREPX | 30.54 | 0.46 | +1.53% |
| Principal Real Estate Securities R5 | |||
| TVOAX | 50.15 | 0.17 | +0.34% |
| Touchstone Small Cap Value A | |||
| EMILX | 26.46 | -0.50 | -1.85% |
| Lord Abbett Emerging Markets Equity I | |||
| NSNRX | 59.75 | -1.19 | -1.95% |
| Neuberger Small Cap Growth R3 | |||